An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany

Sponsor: Bristol-Myers Squibb
Study ID: NCT06169956
Status: Recruiting

Apply to this trial

Conditions

Resectable Non-small Cell Lung Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Neoadjuvant nivolumab in combination with platinum-based chemotherapy — DRUG
Neoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics

Study Details

The purpose of this observational study is to collect and evaluate real-world data to assess the effectiveness of neoadjuvant nivolumab when given in combination with platinum-based chemotherapy in participants with early-stage, resectable non-small cell lung cancer (NSCLC) in Germany

Key Dates

Start date: Nov 30, 2023
Status verified: Apr 2024
Primary completion: Sep 30, 2030
Completion: Sep 30, 2030

Study Design

Enrollment: 400 participants (estimated)

Arms

Arm: Participants receiving neoadjuvant nivolumab in combination with platinum-based chemotherapy

Primary Outcome Measure

Event-free survival [ Time Frame: Up to 5 years ]

Central Contacts

BMS Study Connect Contact Center www.BMSStudyConnect.com
855-907-3286
[email protected]
First line of the email MUST contain NCT # and Site #.